{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:33:41Z","timestamp":1792553621062,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"26","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.vaccine.2022.04.098","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T22:23:57Z","timestamp":1652307837000},"page":"3573-3580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Enhanced surveillance for adverse events following immunization during the 2019 typhoid conjugate vaccine campaign in Harare, Zimbabwe"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7088-5754","authenticated-orcid":false,"given":"Anna","family":"Shaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilda A.","family":"Mujuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuko","family":"Takamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Ticklay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kusum","family":"Nathoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandini","family":"Sreenivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Nyambayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillomina","family":"Chitando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Marembo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colline","family":"Koline Chigodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Mukaratirwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vengai","family":"Jacha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane F.","family":"Gidudu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell","family":"Rupfutse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujeet","family":"Kumar Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Portia","family":"Manangazira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah D.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.vaccine.2022.04.098_b0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114702","article-title":"Descriptive epidemiology of typhoid fever during an epidemic in Harare, Zimbabwe, 2012","volume":"9","author":"Polonsky","year":"2014","journal-title":"PLoS ONE"},{"issue":"11","key":"10.1016\/j.vaccine.2022.04.098_b0010","doi-asserted-by":"crossref","first-page":"342","DOI":"10.15585\/mmwr.mm6711a7","article-title":"Notes from the Field: Typhoid Fever Outbreak - Harare, Zimbabwe, October 2016-March 2017","volume":"67","author":"Davis","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.098_b0015","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1186\/s12879-019-4114-0","article-title":"Laboratory characterisation of Salmonella enterica serotype Typhi isolates from Zimbabwe, 2009\u20132017","volume":"19","author":"Mashe","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2022.04.098_b0020","unstructured":"World Health Organization. Typhoid vaccine prequalified. Available at: https:\/\/www.who.int\/medicines\/news\/2017\/WHOprequalifies-breakthrough-typhoid-vaccine\/en\/. Accessed October 10, 2018."},{"issue":"3","key":"10.1016\/j.vaccine.2022.04.098_b0025","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/cid\/civ295","article-title":"Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study","volume":"61","author":"Mohan","year":"2015","journal-title":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"},{"issue":"10111","key":"10.1016\/j.vaccine.2022.04.098_b0030","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/S0140-6736(17)32149-9","article-title":"Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial","volume":"390","author":"Jin","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"2","key":"10.1016\/j.vaccine.2022.04.098_b0035","first-page":"13","article-title":"30 November - 1 December 2016","volume":"92","author":"Global Advisory Committee on Vaccine Safety","year":"2017","journal-title":"Wkly Epidem Record"},{"key":"10.1016\/j.vaccine.2022.04.098_b0040","doi-asserted-by":"crossref","unstructured":"Poncin M, Marembo J, Sreenivasan N, Makwara I, Machekanyanga Z, Nyabyenda W, et al. Implementation of an Outbreak Response Vaccination Campaign with Typhoid Conjugate Vaccine\u2013Harare, Zimbabwe, 2019. SSRN preprint. 2022.","DOI":"10.2139\/ssrn.4007268"},{"issue":"19","key":"10.1016\/j.vaccine.2022.04.098_b0045","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1016\/j.vaccine.2020.03.028","article-title":"Adverse events following immunization with typhoid conjugate vaccine in an outbreak setting in Hyderabad","volume":"38","author":"Qamar","year":"2020","journal-title":"Pakistan Vaccine"},{"key":"10.1016\/j.vaccine.2022.04.098_b0050","unstructured":"Council for International Organizations of Medical Sciences. Definition and application of terms for vaccine pharmacovigilance. Report of CIOMS\/WHO Working Group on Vaccine Pharmacovigilance. 2012."},{"key":"10.1016\/j.vaccine.2022.04.098_b0055","unstructured":"Ministry of Health and Child Care Z. Adverse Events Following Immunization (AEFI) Surveillance Guidelines. 3rd ed, 2016."},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.098_b0060","first-page":"1","volume":"19","author":"Masuka","year":"2019","journal-title":"Adverse events following immunisation (AEFI) reports from the Zimbabwe expanded programme on immunisation (ZEPI): an analysis of spontaneous reports in Vigibase\u00ae"},{"key":"10.1016\/j.vaccine.2022.04.098_b0065","doi-asserted-by":"crossref","first-page":"308","DOI":"10.11604\/pamj.2017.28.308.12730","article-title":"Evaluation of the adverse events following immunizations surveillance system in Harare City, Zimbabwe, 2016: a descriptive cross sectional study","volume":"28","author":"Zvanaka","year":"2017","journal-title":"The Pan African medical journal"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.098_b0070","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1186\/s12884-018-2092-7","article-title":"Incidence of maternal near miss in the public health sector of Harare, Zimbabwe: a prospective descriptive study","volume":"18","author":"Chikadaya","year":"2018","journal-title":"BMC pregnancy childbirth"},{"issue":"4","key":"10.1016\/j.vaccine.2022.04.098_b0075","doi-asserted-by":"crossref","first-page":"e927","DOI":"10.1093\/cid\/ciab059","article-title":"Evaluation of vaccine safety after the first public sector introduction of typhoid conjugate vaccine\u2014Navi Mumbai, India, 2018","volume":"73","author":"Longley","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2022.04.098_b0080","unstructured":"Kohl KS, Bonhoeffer J, Braun MM, Chen RT, Duclos P, Heijbel H, et al. The Brighton Collaboration: Creating a Global Standard for Case Definitions (and Guidelines) for Adverse Events Following Immunization. In: Henriksen K, Battles JB, Marks ES, Lewin DI. Advances in Patient Safety: From Research to Implementation (Volume 2: Concepts and Methodology). Rockville (MD): Agency for Healthcare Research and Quality (US), 2005."},{"issue":"31","key":"10.1016\/j.vaccine.2022.04.098_b0085","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"Ruggeberg","year":"2007","journal-title":"Vaccine"},{"issue":"31","key":"10.1016\/j.vaccine.2022.04.098_b0090","doi-asserted-by":"crossref","first-page":"5717","DOI":"10.1016\/j.vaccine.2007.02.067","article-title":"Thrombocytopenia: case definition and guidelines for collection, analysis, and presentation of immunization safety data","volume":"25","author":"Wise","year":"2007","journal-title":"Vaccine"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2022.04.098_b0095","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.vaccine.2003.09.008","article-title":"Generalized convulsive seizure as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation","volume":"22","author":"Bonhoeffer","year":"2004","journal-title":"Vaccine"},{"issue":"31","key":"10.1016\/j.vaccine.2022.04.098_b0100","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1016\/j.vaccine.2007.04.058","article-title":"Aseptic meningitis: case definition and guidelines for collection, analysis and presentation of immunization safety data","volume":"25","author":"Tapiainen","year":"2007","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2022.04.098_b0105","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barre syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"issue":"31","key":"10.1016\/j.vaccine.2022.04.098_b0110","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1016\/j.vaccine.2007.04.060","article-title":"Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"25","author":"Sejvar","year":"2007","journal-title":"Vaccine"},{"issue":"31","key":"10.1016\/j.vaccine.2022.04.098_b0115","doi-asserted-by":"crossref","first-page":"5707","DOI":"10.1016\/j.vaccine.2007.02.068","article-title":"Unexplained sudden death, including sudden infant death syndrome (SIDS), in the first and second years of life: case definition and guidelines for collection, analysis, and presentation of immunization safety data","volume":"25","author":"Jorch","year":"2007","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2022.04.098_b0120","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.jaci.2018.12.1003","article-title":"Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990\u20132016","volume":"143","author":"Su","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2022.04.098_b0125","unstructured":"Dobility I. SurveyCTO. Cambridge, Massachusetts."},{"key":"10.1016\/j.vaccine.2022.04.098_b0130","unstructured":"Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification second edition, 2019 update. Geneva: World Health Organization, 2019."},{"key":"10.1016\/j.vaccine.2022.04.098_b0135","series-title":"ICD-10: International statistical classification of diseases and related health problems: Tenth revision","author":"World Health Organization","year":"2004"},{"key":"10.1016\/j.vaccine.2022.04.098_b0140","series-title":"A language and environment for statistical computing","author":"R Core Team. R","year":"2018"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.098_b0145","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/epi4.12035","article-title":"Prevalence, causes, and behavioral and emotional comorbidities of acute symptomatic seizures in Africa: A critical review","volume":"2","author":"Kariuki","year":"2017","journal-title":"Epilepsia open"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2022.04.098_b0150","doi-asserted-by":"crossref","first-page":"B46","DOI":"10.1016\/j.vaccine.2011.12.112","article-title":"Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010","volume":"30","author":"Ouandaogo","year":"2012","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.098_b0155","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2431-8-5","article-title":"The incidence, aetiology and outcome of acute seizures in children admitted to a rural Kenyan district hospital","volume":"8","author":"Idro","year":"2008","journal-title":"BMC Pediatrics"},{"key":"10.1016\/j.vaccine.2022.04.098_b0160","unstructured":"CIOMS Guide to active vacine safety surveillance: report of CIOMS Working Group on Vaccine Safety. Geneva, Switzerland: Council for International Organizations of Medical Sciences (CIOMS), 2017."},{"issue":"12","key":"10.1016\/j.vaccine.2022.04.098_b0165","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/j.vaccine.2018.02.012","article-title":"Use of a new global indicator for vaccine safety surveillance and trends in adverse events following immunization reporting 2000\u20132015","volume":"36","author":"Lei","year":"2018","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2022.04.098_b0170","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.vaccine.2019.11.050","article-title":"Barriers to adverse events following immunization (AEFI) reporting among healthcare workers in four regions of Ghana","volume":"38","author":"Gidudu","year":"2020","journal-title":"Vaccine"},{"issue":"16","key":"10.1016\/j.vaccine.2022.04.098_b0175","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1056\/NEJMoa1713909","article-title":"Evaluation of Intussusception after Monovalent Rotavirus Vaccination in Africa","volume":"378","author":"Tate","year":"2018","journal-title":"New England J Medicine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22005515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22005515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:14:49Z","timestamp":1759403689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22005515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":35,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S0264410X22005515"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.098","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced surveillance for adverse events following immunization during the 2019 typhoid conjugate vaccine campaign in Harare, Zimbabwe","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.098","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}